Cochrane · systematic review · CD010316
First‐line combination therapy versus first‐line monotherapy for primary hypertension
Garjón, J, Saiz, LC, Azparren, A, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
10
current version
GRADE rated
10
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 10 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyCombination therapy compared to monotherapy for primary hypertension
Population: people with primary hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total mortality Combination therapy vs monotherapy | RR 1.35 [0.08, 21.72] | 3 studies · 568 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Cardiovascular mortality Combination therapy vs monotherapy | no estimate extracted | 3 studies · 568 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Cardiovascular events Combination therapy vs monotherapy | RR 0.98 [0.22, 4.41] | 3 studies · 568 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Serious adverse events Combination therapy vs monotherapy | RR 0.77 [0.31, 1.92] | 3 studies · 568 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Withdrawals due to adverse effects Combination therapy vs monotherapy | RR 0.85 [0.53, 1.35] | 3 studies · 568 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Combination with potassium‐sparing diuretics versus monotherapy for primary hypertension
Population: people with primary hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total mortality Combination with potassium‐sparing diuretics vs monotherapy | RR 0.24 [0.01, 5.87] | 1 study · 200 participants | Very low Downgraded: risk of bias, imprecision |
Cardiovascular mortality Combination with potassium‐sparing diuretics vs monotherapy | no estimate extracted | 1 study · 200 participants | Very low Downgraded: risk of bias, imprecision |
Cardiovascular events Combination with potassium‐sparing diuretics vs monotherapy | RR 1.45 [0.13, 15.71] | 1 study · 200 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Combination with potassium‐sparing diuretics vs monotherapy | RR 0.72 [0.1, 5.04] | 1 study · 200 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawals due to adverse effects Combination with potassium‐sparing diuretics vs monotherapy | no estimate extracted | 1 study · 200 participants | Very low Downgraded: risk of bias, imprecision |
Combination therapy versus monotherapy for primary hypertension
Population: people with primary hypertension
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Total mortality Combination therapy vs monotherapy | RR 1.35 [0.08, 21.72] | 3 studies · 568 participants | Very low Downgraded: imprecision |
Cardiovascular mortality Combination therapy vs monotherapy | no estimate extracted | 3 studies · 568 participants | Very low |
Cardiovascular events Combination therapy vs monotherapy | RR 0.98 [0.22, 4.41] | 3 studies · 568 participants | Very low Downgraded: imprecision |
Serious adverse events Combination therapy vs monotherapy | RR 0.77 [0.31, 1.92] | 3 studies · 568 participants | Very low |
Withdrawals due to adverse effects Combination therapy vs monotherapy | RR 0.85 [0.53, 1.35] | 3 studies · 568 participants | Very low |